Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)

BACKGROUND: Pancreatic cancer is susceptible to gemcitabine resistance, and patients receive less benefit from gemcitabine chemotherapy. Previous studies report that gambogic acid possesses antineoplastic properties; however, to our knowledge, there have been no specific studies on its effects in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Guanggai, Wang, Hongcheng, Song, Ziliang, Meng, Qingcai, Huang, Xiuyan, Huang, Xinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553806/
https://www.ncbi.nlm.nih.gov/pubmed/28797284
http://dx.doi.org/10.1186/s13046-017-0579-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553806/
https://www.ncbi.nlm.nih.gov/pubmed/28797284
http://dx.doi.org/10.1186/s13046-017-0579-0

Ejemplares similares